Drug Information

Drug (ID: DG01488) and It's Reported Resistant Information

• Name: N-arachidonoyl dopamine
• Synonyms: NADA; N-Arachidonoyl dopamine; Arachidonoyl dopamine; 199875-69-9; N-Arachidonyldopamine; N-Arachidonyl dopamine; Arachidonyl dopamine; N-arachidonoyldopamine; (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide; CHEMBL138921; CHEBI:31231; N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-dopamine; N-[2-(3,4-Dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide; NADA dopamine; 5,8,11,14-Eicosatetraenamide, N-[2-(3,4-dihydroxyphenyl)ethyl]-,(5Z,8Z,11Z,14Z)-; AA-DA; n-arachidonoyl-dopamine; SCHEMBL154051; BML3-G03; GTPL4261; N-arachidonoyl-dopamine (NADA); BDBM20462; DTXSID70415208; HMS3649B19; ZINC4102443; 1907AH; LMFA08020084; AKOS015951332; NCGC00161231-03; NCGC00161231-04; NCGC00161231-05; HY-110018; SR-01000946639; Q3869319; SR-01000946639-1; Arachidonoyl dopamine, >=98% (HPLC), ethanol solution
• Indication:
  In total 1 Indication(s)
  Bacterial infection [ICD-11: 1A00-1C4Z]; Investigative; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: 17
• IsoSMILES: CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCC1=CC(=C(C=C1)O)O
• InChI: InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-
• InChIKey: MVVPIAAVGAWJNQ-DOFZRALJSA-N
• PubChem CID: 5282105
• ChEBI ID: CHEBI:31231
• TTD Drug ID: D00YCO

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase Nras (NRAS) [1]

• Molecule Alteration: Missense mutation; p.G12D (c.35G>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Ba/F3 cells; Colon; Homo sapiens (Human); CVCL_0161
• In Vitro Model: NIH3T3 cells; Embryo; Homo sapiens (Human); N.A.
• In Vitro Model: WEHI-3 cells; Peripheral blood; Mus musculus (Mouse); CVCL_3622
• In Vitro Model: Bosc23 cells; Fetal kidney; Homo sapiens (Human); CVCL_4401
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Promega assay
• Mechanism Description: N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.

References

• Ref 1: N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane TranslocationMol Cancer Ther. 2017 Jan;16(1):57-67. doi: 10.1158/1535-7163.MCT-16-0419. Epub 2016 Oct 19.